New Therapeutic Approaches to and Mechanisms of Ginsenoside Rg1 Against Neurological Diseases

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Aug 26

PMID 36010610

Authors

Yang Sun

Yantao Yang

Shasha Liu

Songwei Yang

Chen Chen

Meiyu Lin

Qi Zeng

Junpeng Long

Jiao Yao

Fan Yi

Lei Meng

Qidi Ai

Naihong Chen

Affiliations

Soon will be listed here.

Abstract

Neurological diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), stroke, cerebral infarction, ischemia-reperfusion injury, depression and, stress, have high incidence and morbidity and often lead to disability. However, there is no particularly effective medication against them. Therefore, finding drugs with a suitable efficacy, low toxicity and manageable effects to improve the quality of life of patients is an urgent problem. Ginsenoside Rg1 (Rg1) is the main active component of ginseng and has a variety of pharmacological effects. In this review, we focused on the therapeutic potential of Rg1 for improving neurological diseases. We introduce the mechanisms of Ginsenoside Rg1 in neurological diseases, including apoptosis, neuroinflammation, the microRNA (miRNA) family, the mitogen-activated protein kinase (MAPK) family, oxidative stress, nuclear factor-κB (NF-κB), and learning and memory of Rg1 in neurological diseases. In addition, Rg1 can also improve neurological diseases through the interaction of different signal pathways. The purpose of this review is to explore more in-depth ideas for the clinical treatment of neurological diseases (including PD, AD, HD, stroke, cerebral infarction, ischemia-reperfusion injury, depression, and stress). Therefore, Rg1 is expected to become a new therapeutic method for the clinical treatment of neurological diseases.

Citing Articles

A narrative review of : Unique saponins and their pharmacological activities.

Li W, Shi H, Wu X J Ginseng Res. 2025; 49(2):118-133.

PMID: 40061484 PMC: 11889391. DOI: 10.1016/j.jgr.2024.12.005.

The spectrum-efficacy correlation of Kai-Xin-San for cognition of Aβ transgenic and verification of its active ingredients.

Wu J, Sun H, Zhao Y, Lian L, Bian H, Guo Y Front Pharmacol. 2025; 16:1538837.

PMID: 39936091 PMC: 11811076. DOI: 10.3389/fphar.2025.1538837.

Human disease-related long noncoding RNAs: Impact of ginsenosides.

Jang S, Lee H, Kim H, Baek M, Jung S, Kim S J Ginseng Res. 2024; 48(4):347-353.

PMID: 39036728 PMC: 11258377. DOI: 10.1016/j.jgr.2024.04.002.

Ginsenoside Rg1 Regulates Immune Microenvironment and Neurological Recovery After Spinal Cord Injury Through MYCBP2 Delivery via Neuronal Cell-Derived Extracellular Vesicles.

Rong Y, Wang J, Hu T, Shi Z, Lang C, Liu W Adv Sci (Weinh). 2024; 11(31):e2402114.

PMID: 38896802 PMC: 11336912. DOI: 10.1002/advs.202402114.

Ginsenosides for the treatment of insulin resistance and diabetes: Therapeutic perspectives and mechanistic insights.

Kim T J Ginseng Res. 2024; 48(3):276-285.

PMID: 38707641 PMC: 11068994. DOI: 10.1016/j.jgr.2024.03.002.

References

Xu T, Shen X, Sun L, Chen Y, Zhang B, Huang D . Ginsenoside Rg1 protects against H2O2‑induced neuronal damage due to inhibition of the NLRP1 inflammasome signalling pathway in hippocampal neurons in vitro. Int J Mol Med. 2018; 43(2):717-726. PMC: 6317692. DOI: 10.3892/ijmm.2018.4005. View

Toman N, Grande A, Low W . Neural Repair in Stroke. Cell Transplant. 2019; 28(9-10):1123-1126. PMC: 6767877. DOI: 10.1177/0963689719863784. View

Yang X, Chu S, Wang Z, Li F, Yuan Y, Chen N . Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum. Acta Pharmacol Sin. 2020; 42(9):1409-1421. PMC: 8379213. DOI: 10.1038/s41401-020-00558-4. View

Song L, Xu M, Zhou X, Zhang D, Zhang S, Zheng G . A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease. Oxid Med Cell Longev. 2017; 2017:2163053. PMC: 5366755. DOI: 10.1155/2017/2163053. View

He C, Feng R, Sun Y, Chu S, Chen J, Ma C . Simultaneous quantification of ginsenoside Rg1 and its metabolites by HPLC-MS/MS: Rg1 excretion in rat bile, urine and feces. Acta Pharm Sin B. 2016; 6(6):593-599. PMC: 5071637. DOI: 10.1016/j.apsb.2016.05.001. View

Wang Q, Yang L, Peng Y, Gao M, Yang M, Xing W . Ginsenoside Rg1 Regulates SIRT1 to Ameliorate Sepsis-Induced Lung Inflammation and Injury via Inhibiting Endoplasmic Reticulum Stress and Inflammation. Mediators Inflamm. 2019; 2019:6453296. PMC: 6409002. DOI: 10.1155/2019/6453296. View

Kim J, Byeon H, Im K, Min H . Effects of ginsenosides on regulatory T cell differentiation. Food Sci Biotechnol. 2018; 27(1):227-232. PMC: 6049740. DOI: 10.1007/s10068-017-0255-3. View

Vavakova M, Durackova Z, Trebaticka J . Markers of Oxidative Stress and Neuroprogression in Depression Disorder. Oxid Med Cell Longev. 2015; 2015:898393. PMC: 4453280. DOI: 10.1155/2015/898393. View

Menozzi E, Macnaughtan J, Schapira A . The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med. 2021; 53(1):611-625. PMC: 8078923. DOI: 10.1080/07853890.2021.1890330. View

10.

Labbadia J, Morimoto R . Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci. 2013; 38(8):378-85. PMC: 3955166. DOI: 10.1016/j.tibs.2013.05.003. View

11.

Yang Y, Li S, Huang H, Lv J, Chen S, Dias A . Comparison of the Protective Effects of Ginsenosides Rb1 and Rg1 on Improving Cognitive Deficits in SAMP8 Mice Based on Anti-Neuroinflammation Mechanism. Front Pharmacol. 2020; 11:834. PMC: 7298198. DOI: 10.3389/fphar.2020.00834. View

12.

Ahmed T, Raza S, Maryam A, Setzer W, Braidy N, Nabavi S . Ginsenoside Rb1 as a neuroprotective agent: A review. Brain Res Bull. 2016; 125:30-43. DOI: 10.1016/j.brainresbull.2016.04.002. View

13.

Quan Q, Li X, Yuan H, Wang Y, Liu W . Ginsenoside Rg1 inhibits high-voltage-activated calcium channel currents in hippocampal neurons of beta-amyloid peptide-exposed rat brain slices. Chin J Integr Med. 2016; . DOI: 10.1007/s11655-015-2301-4. View

14.

Liu J, Zhao M, Zhang Z, Cui L, Zhou X, Zhang W . Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-κB signaling and modulation of M1/M2 polarization. Acta Pharmacol Sin. 2020; 41(4):523-534. PMC: 7468333. DOI: 10.1038/s41401-020-0358-x. View

15.

Huang Q, Zhong W, Hu Z, Tang X . A review of the role of cav-1 in neuropathology and neural recovery after ischemic stroke. J Neuroinflammation. 2018; 15(1):348. PMC: 6302517. DOI: 10.1186/s12974-018-1387-y. View

16.

Wang Y, Liu Q, Xu Y, Zhang Y, Lv Y, Tan Y . Ginsenoside Rg1 Protects against Oxidative Stress-induced Neuronal Apoptosis through Myosin IIA-actin Related Cytoskeletal Reorganization. Int J Biol Sci. 2016; 12(11):1341-1356. PMC: 5118780. DOI: 10.7150/ijbs.15992. View

17.

Huang L, Liu L, Liu J, Dou L, Wang G, Liu X . Ginsenoside Rg1 protects against neurodegeneration by inducing neurite outgrowth in cultured hippocampal neurons. Neural Regen Res. 2016; 11(2):319-25. PMC: 4810998. DOI: 10.4103/1673-5374.177741. View

18.

Sun M, Ye Y, Xiao L, Duan X, Zhang Y, Zhang H . Anticancer effects of ginsenoside Rg3 (Review). Int J Mol Med. 2017; 39(3):507-518. DOI: 10.3892/ijmm.2017.2857. View

19.

Zheng X, Ma S, Kang A, Wu M, Wang L, Wang Q . Chemical dampening of Ly6C(hi) monocytes in the periphery produces anti-depressant effects in mice. Sci Rep. 2016; 6:19406. PMC: 4725984. DOI: 10.1038/srep19406. View

20.

Ghasemi R, Dargahi L, Haeri A, Moosavi M, Mohamed Z, Ahmadiani A . Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol Neurobiol. 2013; 47(3):1045-65. DOI: 10.1007/s12035-013-8404-z. View